New pill RAP-219 aims to tame mania in bipolar disorder

NCT ID NCT07046494

Ongoing Symptom relief Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests an experimental drug called RAP-219 for people with bipolar I disorder who are currently experiencing a manic episode. About 250 participants will receive either RAP-219 or a placebo daily for 21 days. Researchers will measure changes in manic symptoms using a standard rating scale to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAP-219 (oral tablet)
What this could lead to: If it works, this could provide a new short-term treatment option to quickly reduce manic symptoms in people with bipolar I disorder.
What could go wrong: This is an early Phase 2 trial with only 250 participants, so results may not apply to everyone. The drug may prove no better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar I disorder Mania

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR 1 DISORDER

Contacts and locations

Locations

Arch Clinical Trials

St Louis, Missouri, 63125, United States
CenExel - Decatur

Decatur, Georgia, 30030, United States
CenExel - Gaithersburg

Gaithersburg, Maryland, 20877, United States
CenExel - Hollywood

Hollywood, Florida, 33024, United States
Collaborative Neuroscience Research - Los Alamitos

Los Alamitos, California, 90720, United States
Community Clinical Research, Inc.

Austin, Texas, 78754, United States
HD Research - Memorial Hermann Village

Houston, Texas, 77043, United States
Inland Psychiatric Medical Group - Chino

Chino, California, 91710, United States
NRC Research Institute - Orange

Orange, California, 92868, United States
NeuroBehavioral Hospitals of the Palm Beaches - South

Boynton Beach, Florida, 33426, United States
Neuroscience Research Institute at Ambrosia

West Palm Beach, Florida, 33407, United States
New Hope Clinical Research

Charlotte, North Carolina, 28211, United States
Pillar Clinical Research - Chicago

Chicago, Illinois, 60641, United States
Pillar Clinical Research - Little Rock

Little Rock, Arkansas, 72204, United States
Pillar Clinical Research - Richardson

Richardson, Texas, 75080, United States
Richmond Behavioral Associates

Staten Island, New York, 10314, United States
Segal Trials - Miami Lakes Medical Research Early Phase, Inpatient & Outpatient Site

Miami Lakes, Florida, 33016, United States
Synergy Clinical Research Center - San Diego

Lemon Grove, California, 91945, United States
United Research Institute

Hialeah, Florida, 33012, United States
Woodland Research Northwest

Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.